Topic: antibody drug conjugates
Enhertu cut the risk of death by 41% compared with chemo in previously treated HER2-positive gastric cancer.
Roche offers a confidential discount off Kadcyla's average per-patient list price of £51,000 for adjuvant breast cancer routine coverage.
Gilead's remdesivir has won an "exceptional approval" in Japan. Eli Lilly has paired up with China's Junshi on coronavirus neutralizing antibodies.
Immunomedics weathered a nixed licensing deal, two manufacturing slapdowns, a complete response letter and a C-suite overhaul to win its new FDA nod.
Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.
A Chinese company's producing a remdesivir generic. Daiichi expects $18 million in Enhertu Q1 sales. Tecentriq becomes seventh PD-1/L1 to enter China.
11 would-be blockbusters span several therapeutic areas, including CNS, oncology, hematology, inflammatory diseases and metabolic disorders.
Thanks to clear clinical benefits and two well-prepared sales team, Enhertu could be looking at $18 million in sales in Q1, Daiichi U.S. chief said.
Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.
Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.